We are proud to introduce Zena's first journal publication, reflecting our mission and outlining our strategy for improving the safety of pharmacotherapies for everyone!

The list profiles companies “pursuing new and better ways of doing things we all do every day”, according to NJ Biz.

Our team is honored to be featured in a Rutgers news article, shining a spotlight on the important work we do.

The Zena Team is grateful to have been selected for Princeton Innovation Center BioLabs Investor Day! Our very own Eileen Carry, PhD delivered a fantastic soft pitch to investors that informed the audience of the important work we are doing here at Zena. We couldn’t be more proud!

The team at Zena could not be happier with the exciting news of receiving seed funding from Foundation Venture Capital Group, the investment arm of New Jersey Health Foundation (NJHF). NJHF has been partnered with the Zena team since the very beginning funding Dr. Eileen Carry’s dissertation work that turned foundational innovation launching Zena! We couldn’t be happier continuing this partnership and going the distance with our new investors!

Zena is proud to announce that we have been awarded a Phase I STTR from the National Institutes of Health- NIDA! This project entitled “Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities” is in partnership with Rutgers University, the Dr. Nicholas Bello lab, and will generate foundational research investigating the threshold of overdoes with concomitant use of opioids and anxiolytic medications.

We say a bittersweet farewell to our home at our alma mater, Rutgers University, but are excited to embark on our new adventure at the New Jersey Bioscience Center! We can’t wait to explore our new surroundings and expand the vision of Zena!